Colchicine binding site-targeting microtubule inhibitor therapy(BridGene Biosciences/University of Tennessee) | Interleukin Related interleukin-related.com

Product Name :
Colchicine binding site-targeting microtubule inhibitor therapy(BridGene Biosciences/University of Tennessee)

Search keywords :
Colchicine

drugId :
null

Target Vo:
Tubulin

Target Vo Short Name :
Tubulin

Moa_Name:
Tubulin inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
BridGene Biosciences Inc

Active Company_Name :
BridGene Biosciences Inc

Active Indication_Name:
Triple Negative Breast Neoplasms

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Ras Rabbit mAb Epigenetic Reader Domain
Tifcemalimab Protocol
CD127 Antibody: CD127 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 52 kDa, targeting to CD127. It can be used for WB assays with tag free, in the background of Human.

Author: Interleukin Related

Related Posts